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ABSTRACT
Extensive genome-wide analyses of deregulated gene expression have now 
been performed for many types of cancer. However, most studies have focused 
on deregulation at the gene-level, which may overlook the alterations of specific 
transcripts for a given gene. Clear cell renal cell carcinoma (ccRCC) is one of the best-
characterized and most pervasive renal cancers, and ccRCCs are well-documented 
to have aberrant RNA processing. In the present study, we examine the extent of 
aberrant isoform-specific RNA expression by reporting a comprehensive transcript-
level analysis, using the new kallisto-sleuth-RATs pipeline, investigating coding and 
non-coding differential transcript expression in ccRCC. We analyzed 50 ccRCC tumors 
and their matched normal samples from The Cancer Genome Altas datasets. We 
identified 7,339 differentially expressed transcripts and 94 genes exhibiting differential 
transcript isoform usage in ccRCC. Additionally, transcript-level coexpression network 
analyses identified vasculature development and the tricarboxylic acid cycle as the 
most significantly deregulated networks correlating with ccRCC progression. These 
analyses uncovered several uncharacterized transcripts, including lncRNAs FGD5-AS1 
and AL035661.1, as potential regulators of the tricarboxylic acid cycle associated with 
ccRCC progression. As ccRCC still presents treatment challenges, our results provide 
a new resource of potential therapeutics targets and highlight the importance of 
exploring alternative methodologies in transcriptome-wide studies.
INTRODUCTION
Renal cancer is one of the ten most frequently 
occurring cancers found in both males and females in 
the United States [1]. In 2018, an estimated 65,340 new 
cases of renal cancer will be diagnosed within the US 
with ~96% of them being renal cell carinomas (RCC) 
[2]. Most RCC tumors originate from the epithelial cells 
of proximal tubules within the cortex of the kidney, and 
RCCs carry with them several therapeutics challenges 
[3, 4]. Specifically, both chemotherapy and radiation 
treatments are largely ineffective, patients can be 
frequently asymptotic, and metastatic RCC has a relatively 
high 5-year mortality rate of > 90% [5]. Among the four 
major histological RCC subtypes, clear cell renal cell 
carcinoma (ccRCC) is the most common, observed within 
75% of cases [6].
One of the characteristic features of ccRCC is the 
frequently mutated von Hippel-Lindau (VHL) gene, 
found within ~50% of ccRCC tumors, or loss of the 
short arm of chromosome 3 [7–10]. Loss of a functional 
VHL protein, a E3 ubiquitin ligase, results in enhanced 
stability of a family of transcription factors, known as 
hypoxia inducible transcription factors (HIFs) [11]. As 
a result of elevated HIF proteins, changes to expression 
levels of several HIF responsive genes can occur, such as 
vascular endothelial growth factor (VEGF), MET proto-
oncogene (c-MET), and transforming growth factor (TGF), 
altering the pro-angiogenic, invasive and proliferative 
characteristics of cancer cells. With the advent of large-
platform and high-throughout techniques, we have greatly 
improved our understanding of the VHL/HIF pathway, 
and we have expanded beyond this classical model to 
reveal other key molecular events that occur in ccRCC. 
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In a recent comprehensive study examining ccRCC, an 
integrative pathway analysis showed one of the most 
frequently mutated subnetworks were genes that influence 
the epigenetic landscape, such as PBRM1 and genes in the 
PBAF SWI/SNF chromatin remodeling complex [7]. 
However, despite the shift to global gene expression 
profiling, little attention has been given to examining 
transcript-specific changes in ccRCC and other cancers, 
possibly due to the additional computational constraints 
compared to conventional gene-level analyses. Aberrant 
transcript isoforms from altered transcription initiation, 
termination and RNA processing (including altered 
alternative splicing) are well-documented phenomena 
found within many cancers [8, 12–15]. Furthermore, 
abnormal RNA processing events can have profound effects 
on the function of coding and non-coding RNA species 
[16, 17]. In a recent example, inactivation of a histone 
methyltransferase, known as SET domain containing 2 
(SETD2), was discovered to be one of the inciting causes 
of widespread transcriptional read-through and abnormal 
RNA chimera production found in ccRCC [16]. 
With the advent of alignment-free RNA-Seq 
quantification algorithms, larger scale and more 
comprehensive transcript-level analyses can now be 
performed with a smaller computational footprint. An 
example is kallisto, one of the fastest and most accurate 
transcript-level quantification programs. Instead of more 
time consuming read alignments, it uses a k-mer approach 
for quantifying the abundance of transcripts in RNA-
seq experiments [18]. More recently, two R packages, 
sleuth and RATs (Relative Abundance of Transcripts), 
were developed that exploit the bootstrap estimates 
from kallisto to identify events of differential transcript 
expression and differential transcript usage, respectively 
[19, 20]. Differential transcript expression (DTE) is any 
change in the relative abundance of a transcript between 
two conditions. Alternatively, differential transcript usage 
(DTU) is the proportional change of the transcripts that 
a gene encodes. For example, DTU can frequently result 
in isoform-switching, in which the major isoform (most 
abundant) “switches” with an alternative transcript, and 
thereby that isoform is longer the major isoform of that 
particular gene. To our knowledge, there are relatively 
few transcriptome-level studies examining differential 
transcript expression in ccRCC, and these studies have 
either relied on microarray platforms or focused largely 
on one aspect of differential transcript expression (e.g. 
differential splicing) [21–26]. Importantly, transcript-level 
analyses can add greater resolution to a transcriptome-
wide study, as significant DTE can evade traditional gene-
level analysis techniques. 
The current study uses a multifaceted approach 
with new highly accurate computational methods, not 
employed by previous studies, quantifying all transcript-
level alterations in ccRCC, and places these alterations 
in the context of key biological pathways involved 
in ccRCC progression (Figure 1A). In doing so, we 
identified several previously uncharacterized deregulated 
genes implicated in ccRCC. We analyzed 100 RNA-seq 
datasets (50 matched pair samples) from The Cancer 
Genome Altas (TCGA) with kallisto to quantify all 
putative coding and non-coding transcripts, sleuth to 
identify significant differentially expressed transcripts 
(DETs) and RATs to discover events of differential 
transcript usage (DTU). We identified 7,339 DETs and 
94 DTU genes of which 68 genes are uncharacterized. 
Furthermore, we performed a comparative differential 
expression analysis, using both gene-level and transcript-
level analyses, and identified novel deregulated genes 
in ccRCC. Additionally, we performed one of the first 
weighted transcript-level coexpression network analyses 
in ccRCC. Using WGCNA, we found that transcript 
networks controlling vascular development and TCA 
cycle were most significantly deregulated and correlated 
with ccRCC tumor stage. These analyses identified 
several uncharacterized genes as potential modulators of 
pathways deregulated in ccRCC.
RESULTS
Global identification and validation of DTE in 
ccRCC
From the kallisto analysis, a total of 217,082 
transcripts quantifications (160,717 protein-coding and 
56,365 non-coding) for each of the 100 samples were 
used in the differential expression analyses, comparing 50 
normal adjacent renal samples against 50 ccRCC samples. 
Using the Wald test, with a log2 transformation, 90,002 
transcripts passed the initial filtering process used by the 
sleuth R package. With a q-value of < 0.005, we identified 
32,642 DETs, encoded by 14,767 genes (Supplementary 
Table 1, Supplementary Figure 1). With additional 
filtering, using the bias estimator, referred to as the beta 
value of > 1 or < -1 and an average absolute transcript 
expression of > 1 TPM, 7,339 high confidence DETs were 
identified (Figure 1B, Supplementary Table 1). 
Gene ontology analyses using the express analysis 
in Metascape of the unique genes encoding the DETs are 
consistent with previous reports (Supplementary Table 1) 
[25, 27]. There is significant enrichment of gene sets and 
GO terms related to the immune response for the 3,366 
upregulated DETs (encoded by 2,023 genes). Conversely, 
there is enrichment in GO terms related to metabolic 
processes and transport of small molecules and ions for 
the 3,973 downregulatd DETs (encoded by 2,518 genes). 
Previously reported and contained within the 7,339 DETs, 
is ras-related C3 botulinum toxin substrate 1 (RAC1), that 
shows a statistically significant downregulation of one 
of its transcripts, ENST00000356142.4 (Supplementary 
Figure 2) [13]. ENST00000356142.4 contains an 
additional exon, referred to as exon 3b that is frequently 
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spliced out in ccRCC. The most abundant RAC1 transcript, 
ENST00000348035.8, is unaffected in ccRCC. 
As mutations in key epigenetic modifiers, such 
as SETD2, PBRM1 and BAP1, among ccRCCs have 
demonstrated to have significant effects on the epigenetic 
landscape and consequently splicing events, we compared 
the DETs observed in the current study against 6,207 RefSeq 
transcripts previously found to have defects in splicing and 
intron retention [14]. Among the 6,207 transcripts, 6,070 
transcripts were readily converted to an ensembl annotation, 
and 1,857 transcripts were identified as differentially 
expressed. In a similar study, among 30 genes found to have 
a deficiency in H3K36me3 and SETD2-mediated alternative 
splicing [15], we found 27 of these genes to have at least one 
DET in the current study (using an FDR < 0.005).
Among the 7,339 DETs discovered (4,470 individual 
loci), ~89% were protein-coding (6,546 transcripts) and 
~11% were non-coding (793 transcripts) (Figure 1C, 
left).  These DETs represented only ~4% and ~1% of the 
total putative protein-coding and non-coding transcripts, 
respectively (Figure 1C, right). Further characterization of 
the DETs showed that the number of transcripts affected 
remained relatively static, regardless of the number of 
putative transcripts derived from a given gene (Figure 1D). 
With genes encoding ≥ 2 transcripts, > 80% of the genes 
had ≤ 3 detectable DETs. 
Lastly, as previous gene-level expression analyses 
may not have detected some cases of DTE, we performed a 
comparative differential expression analysis of the matched 
pair samples evaluating the results of edgeR and sleuth 
[24] (Figure 2A). For the gene-level edgeR analysis, read 
counts were generated within the systemPipeR package, 
using HISAT2 for the alignment of the sequence reads and 
summarizeOverlaps for the generation of the gene counts. 
With thresholds of > 2 fold change and FDR < 0.005, 
edgeR identified 5,665 differentially expressed genes 
(DEGs). In an alternative gene-level analysis, using kallisto 
generated gene counts, the sleuth gene-level analysis 
discovered 6,441 DEGs, with a beta value of > 1 or < -1 
and a FDR < 0.005. Among the 4470 genes, encoding 
the 7,339 DETs (described above), a total of 1,159 genes 
were found exclusively within the sleuth transcript-level 
analysis (Supplementary Table 1).  Interestingly, only ~4% 
(51 genes) of the 1,159 genes harbored both upregulated 
and downregulated DETs. A moderate degree of overlap 
was observed between the four differential expression 
analyses, sharing 1,581 genes in common. Similarly, all 
gene-level analyses shared 1,932 genes in common, while 
the kallisto gene-level and our edgeR analyses had the most 
in common, sharing 3,632 DEGs.
One example of significant differentially expressed 
transcripts, not detected by gene-level analyses and not 
Figure 1: Global identification of differential transcript expression in ccRCC. (A) Overview of pipeline used in identification 
and characterization of DTE and DTU in ccRCC. (B) Unsupervised hierarchical clustering of 7,339 DETs identified using sleuth (FDR < 
0.005 and beta value of < -1 or > 1). (C) Percentage of protein-coding and non-coding genes for the 7,339 DETs identified using sleuth. (D) 
Proportion of genes with n identified DETs relative to total number of encoded transcripts.
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identified by previous ccRCC studies, are derived from 
Pleckstrin homology like domain family B member 
2 (PHLDB2) known commonly for its association 
with vascular dementia (Figure 2B) [28]. PHLDB2 
encodes for 18 putative transcripts, and two transcripts 
ENST00000393923.7 and ENST00000431670.6 
are downregulated in ccRCC (Supplementary 
Table 1). ENST00000393923.7 is the most abundant 
protein-coding PHLDB2 transcript, and it is the most 
significantly downregulated in ccRCC (Figure 2C). 
ENST00000393925.7 is a slightly less abundant PHLDB2 
transcript, and it is unaffected in ccRCC. Evaluation of 
the tumor/normal TPM ratios of the 50 matched pair 
samples showed that patients with a high degree of 
ENST00000393923.7 downregulation exhibited lower 
survival rates over ~12 years (p = 0.0015, Figure 2D). 
Two additional examples of genes harboring DETs, 
solute carrier family 37 member 3 (SLC37A3) and high-
density lipoprotein binding protein (HDLBP) were also 
found to correlate with patient survival (Supplementary 
Figure 3). ENST00000393923.7 downregulation was 
validated using transcript-specific qPCR with 12 
independent matched pair ccRCC samples (Figure 2E). 
Using a Wilcoxon signed-rank test, ENST00000393923.7 
was found to be significantly downregulated in ccRCC 
with a median downregulation of ~6.3 fold change. No 
statistically significant difference was observed with 
ENST00000393925.7.
Figure 2: Comparative differential expression analysis identifies novel genes implicated in ccRCC. (A) Comparison of 
DEGs/DTE genes discovered with sleuth, edgeR, and a previous study by Scelo et al. (B) Transcript abundances in normal renal and ccRCC 
tissues for the two most abundant PHLDB2 transcripts. Each box plot represents 50 calculated bootstrap values of an individual sample 
(red = normal, blue = ccRCC). (C) ENST00000393923.7 harbors an alternative exon 1 and 2 and excludes exon 6 of ENST00000393925.7. 
Differences colored in blue. (D) Kaplan-Meier plot assessing survival of patients with high vs low/no ENST00000393923.7 downregulation. 
Median T/N ratio was used to partition samples into low/no and high downregulation groups. Log rank test was used to calculate statistical 
significance. (E) qPCR validation of PHLDB2 DTE showing log2 fold change of 12 ccRCC tissues relative to their normal adjacent tissues. 
Results normalized to PPIA reference gene. Two-tailed Wilcoxon signed-rank test was used to determine statistical significance. Error bars 
= average standard deviation of technical replicates of pair samples. ns = non-significant (> 0.05).
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Weighted transcript-level coexpression network 
analysis
As our previous analyses suggest some transcripts 
derived from the same gene exhibiting different expression 
profiles, we sought to better understand the isoform-
specific changes occurring within ccRCCs. Therefore, we 
pursued a weighted coexpression network analysis using 
the calculated transcript quantifications as a framework. 
Using WGCNA and the calculated TPM values from 
10,000 of the most variable transcripts, a coexpression 
network was performed across five stages of ccRCC 
progression (normal, stage I, stage II, stage III, stage IV). 
A total of 26 coexpression modules were identified (Figure 
3A), with 7 coexpression modules highly correlated with 
ccRCC progression (pearson coefficient > 0.5 or < -0.5 and 
p < 0.05). Using the Reactome, KEGG pathway, CORUM 
gene sets and the conventional GO terms, a Metascape 
analysis was performed separately with each of the 7 
correlated coexpression modules. Among the 4 positively 
correlated coexpression modules, vascular development, 
ribosome, cytokine signaling and collagen formation were 
the most enriched terms found within each of the modules. 
Conversely, the 3 negatively correlated coexpression 
modules revealed TCA cycle, extracellular matrix 
organization and organic acid catabolic processes as the 
most significant terms (Supplementary Table 1). Identified 
within each of the modules were transcripts with the 
highest module membership, as these transcripts are likely 
extensively connected intramodular hubs (Figure 3A). 
These transcripts included: ENST00000381125.8 encoded 
by Phosphofructokinase, Platelet (PFKP), 
ENST00000356892.3 encoded by SAM And SH3 
domain containing 3 (SASH3), ENST00000225430.8 
encoded by Ribosomal Protein L19 (RPL19), 
ENST00000296388.9 encoded by Prolyl 3-Hydroxylase 
1 (P3H1), ENST00000295887.5 encoded by CDP-
Diacylglycerol Synthase 1 (CDS1), ENST00000257290.9 
encoded by Platelet Derived Growth Factor Receptor 
Alpha (PDGFRA), and ENST00000354775.4 encoded 
by Aldehyde Dehydrodenase 9 Family Member 1 
(ALDH9A1).
Further characterization of the coexpression 
networks showed that the majority of the transcripts 
comprising the networks, and all the transcripts used in 
the network construction, were encoded from separate 
individuals genes (Supplementary Figure 4). Additionally, 
validation of the network and gene set analyses showed 
24 out of the top 30 coexpressed transcripts (transcripts 
with high adjacency scores) contained within the vascular 
development coexpression module, are derived from 
genes comprising the core signature angiogenesis genes 
described previously (Figure 3B, right) [29]. Moreover, 
among the top 30 coexpressed transcripts contained within 
the TCA coexpression module, 28 transcripts are produced 
by genes previously discovered as being downregulated in 
ccRCC (Figure 3B, left) [30]. The remaining transcripts, 
ENST00000424349.1 encoded by FGD5 antisense 
RNA 1 (FGD5-AS1) and ENST00000620459.1 encoded 
by AL035661.1 are uncharacterized lncRNAs highly 
downregulated in ccRCC. 
Differential transcript usage in ccRCC
Using the kallisto transcript abundances, the RATs 
R package identified 97 events of differential transcript 
usage (Figure 4A, left, Supplementary Figure 5). These 97 
transcripts were identified using the RATs transcript-level 
test, which examines each transcript individually and then 
merges the transcript information to form a gene-level 
finding. Alternatively, the gene-level DTU test, which 
collectively evaluates the transcripts of a gene, identified 
only 26 DTU genes (Figure 4A, right, Supplementary 
Figure 5). Among both transcript-level and gene-level 
DTU tests, 7 DTU genes (AP1M2, CAB39L, CCDC146, 
C16orf89, DAB2, MAPK8IP1, FGFR2) have been 
identified previously [25, 26]. Collectively, 94 DTU genes 
(68 uncharacterized DTU genes) in total were discovered 
(using both DTU tests) when comparing normal adjacent 
and ccRCC tissues (Supplementary Table 1). No 
statistically significant GO terms were enriched within the 
94 DTU genes, using a corrected p-value. However, the 
Metascape analysis showed the top GO term (p = 0.0007) 
was carboxylic acid transport, supporting previous results 
demonstrating metabolic derangements as a cornerstone 
of ccRCC [7, 31]. Seven DTU genes were found to have 
a carboxylic acid transport GO classification, which 
included: AGXT, SLC38A5, SLC9A4, SLC3A2, UNC13B, 
FABP6 and FOLR1.
Examination of the DTU events showed that non-
primary (i.e. non-major) isoform switches are more 
frequent than primary isoform switches in ccRCC (Figure 
4B). On average, we identified approximately twice as 
many non-primary isoform switches relative to primary 
isoform switches. Among the 8 primary isoform switches 
(in common between the DTU tests), all of them also had 
non-primary isoform switches. The DTU genes (described 
previously) AP1M2, DAB2 and FGFR2 exhibited both 
primary and non-primary isoform switching events 
(Supplementary Figures 6–7).  Constituting the majority 
of DTU genes, a total of 76 DTU protein-coding genes 
were observed. The remaining DTU genes encompassed 
11 ncRNA and 7 unclassified genes. Two examples of 
mostly uncharacterized DTU genes, with high isoform-
switch frequencies, were FOLR1 and BABAM2 (Figure 
4C, Supplementary Figure 6). FOLR1, known as folate 
receptor 1, produces 4 putative transcripts, and was 
found to be one of the most significant primary isoform 
switches. ENST00000393676.4 has an alternative 5’ end 
and is the most abundant FOLR1 transcript in normal 
renal tissue (Figure 4D); however, ENST00000393681.6 
switches with ENST00000393676.4 becoming the 
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most abundant or primary FOLR1 transcript in ccRCC. 
FOLR1 had the highest isoform-switch frequency with 
61% of ccRCC samples exhibiting the primary isoform-
switch (Figure 4E). BABAM2 encodes for a component 
of the BRCA1-A complex, and it produces 11 putative 
transcripts, 4 of which were eligible for DTU analysis. 
ENST00000436924.5 was the only BABAM2 transcript to 
show a significant proportional increase in its abundance 
in ccRCC, becoming the second most abundant BABAM2 
transcript in ccRCC (Supplementary Figure 6). 
DISCUSSION
In the current study, we identified the global isoform-
specific alterations in ccRCC and explored the deregulated 
networks implicated in ccRCC progression. Using the 
kallisto-sleuth pipeline, we discovered 7,339 DETs of which 
~90% of the transcripts were derived from protein-coding 
genes. Additionally, comparative differential expression 
and coexpression network analyses aided in the discovery 
of several potentially clinically relevant genes and the major 
deregulated networks in ccRCC progression. Lastly, we 
discovered 68 uncharacterized high-frequency DTU genes 
in ccRCC with a suggested enrichment of genes involved in 
metabolic function. 
Differential exon usage (DEU) has frequently 
been used as an inference for DTE in ccRCC [21, 23, 
25]; however, this approach could present challenges 
in identifying DETs among transcripts sharing exons. 
Additionally, gene-level expression analyses could 
potentially overlook deregulated transcripts from clinically 
relevant genes that give rise to multiple transcripts. 
Therefore, we sought to identify deregulated transcripts 
and cognate genes that were not discovered readily by 
gene-level analyses by using novel methods that are not 
subject to the disadvantages of the DEU approach. In a 
typical gene-level analysis, all exonic reads from a gene 
are consolidated and used to determine if the expression 
of a gene is altered between two conditions. However, 
this approach could be disadvantageous in specific 
circumstances. One potential pitfall to a gene-level 
analysis is that if the other transcripts from the same gene 
are of similar abundance to the DET, then a conventional 
gene-level analysis may not detect a gene-level difference 
Figure 3: Vascular development and TCA cycle coexpression modules are the highest correlated networks in ccRCC 
progression. (A) ccRCC correlated coexpression network modules identified with WGCNA. Using a correlation coefficient of > 0.5 or < 
-0.5 and p < 0.05, 4 positively correlated networks (blue bars, right of dotted line), and 3 negatively networks were identified to be in ccRCC 
(red bars, left of dotted line). Networks with no significant correlation with ccRCC (grey, p > 0.05). Most significant GO term for each 
module shown in bold, and the transcript with the highest module membership shown below. (B) Top 30 highest coexpressed transcripts 
(gene names shown) within the TCA cycle (left) and vascular development modules (right). Novel genes highlighted in red.
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between the two conditions. Additionally, while isoform 
switching was found to be a relatively rare occurrence 
in ccRCC, isoform switching could also account for 
a “masking” of a relevant gene. PHLD2, HDLBP and 
SLC37A3 are examples of this “masking” effect, in which 
DTE was not detected using conventional gene-level 
analyses. While we acknowledge that the degree of overlap 
between gene-level and transcript-level analyses could 
vary greatly depending on methodology and experimental 
thresholds, the current study highlights the importance of 
considering transcript-level analyses in comprehensive 
transcriptome-wide studies. Lastly, comparisons with 
previous studies, focused on SETD2 mutational status/
H3K36me3 prevalence of ccRCC tumors and the resulting 
Figure 4: Few high frequency DTU genes observed in ccRCC. (A) Transcript and gene-level tests using RATs to identify DTU 
events in ccRCC (red dot = non-DTU, blue dot = DTU). (B) Number of primary and non-primary isoform switches discovered in ccRCC. 
“Both” represents the number of shared DTU genes identified in both the transcript and gene-level tests. (C) FOLR1 exhibiting significant 
proportional isoforms changes in ccRCC. Circle = significant DTU. Square = tested in DTU analysis, but not significant. X = did not meet 
abundance threshold for DTU anlaysis. (D) Schematic of FOLR1 transcripts analyzed in DTU analysis. (E) Frequency of FOLR1 and 17 
other isoform switches shared between both DTU tests. 
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effects on splicing [14, 15], suggest that genes subject to 
splicing defects can also harbor DETs. However, additional 
studies with large cohorts of mutation-specific ccRCCs are 
needed to determine isoform-specific expression changes 
that may be dependent on mutational status. As only 12 
ccRCC tumors had a mutated SETD2, in the current study, 
our findings largely reflect SETD2-independent isoform-
specific changes.
The discovery of two uncharacterized transcripts 
encoded by lncRNAs genes FGD5-AS1 and AL035661.1 
identified in the network analysis suggest these lncRNAs 
transcripts could be potential regulators of TCA cycle 
genes or alternatively regulated by a common factor. 
These lncRNAs could be of particular importance to 
understanding ccRCC because of their implications in 
metabolic function. However, further investigation is 
needed, as the function of these lncRNAs is unknown. 
Another interesting transcript found within the TCA cycle 
coexpression module, identified with the highest module 
membership, is ENST00000295887.5 encoded by CDS1. 
CDS1 encodes an integral membrane enzyme, located on 
the membranes of the mitochondrion and endoplasmic 
reticulum, that catalyzes the conversion of phosphatidic 
acid into CDP-diacylaglycerol [32, 33]. CDS1 is 
uncharacterized in ccRCC and there is limited information 
on its role in cancer; however, in a recent study, CDS1 
was suggested to potentiate limitless growth and genomic 
instability in breast cancer [34].
We identified a total of 94 genes exhibiting 
differential transcript usage in ccRCC of which 7 DTU 
genes were reported previously [25, 26]. However, when 
considering the findings of an alternative study [24], 
which also evaluated lower frequency isoform-switches, 
the current study identified 26 DTU genes in common. 
Therefore, the differences observed in the DTU genes are 
likely attributed to different computational techniques/
thresholds and/or the use of different transcript annotations 
[19]. While our findings show that the majority of isoform 
switching events involves non-primary isoforms, which 
is consistent with a previous result [24], alterations in 
the expression of non-primary isoforms could still be 
clinically relevant, as supported by the survival analyses 
seen with the non-primary SLC37A3 and HDLBP 
deregulated transcripts. However, the mechanisms 
involved require further investigation. Recent studies 
have illustrated how isoform-specific alterations could 
be highly influential in ccRCC and other cancers. For 
instance, alternatively spliced isoforms of VHL were 
shown to alter VHL binding affinity to components of the 
p53 pathway [35]. Additionally, isoform-switching events 
have been demonstrated to alter the invasive properties 
of cancer cells [17, 36]. From our analyses and previous 
similar studies, mentioned above, it is highly suggestive 
that isoform-specific deregulations are a critical part 
to characterizing and understanding the molecular 
underpinnings of ccRCC, and suggest that isoform-
level transcriptomic analyses should more generally be 
considered to obtain a more comprehensive view of the 
genetic deregulations in cancer. 
MATERIALS AND METHODS
Transcript quantification and differential 
expression analyses
A total of 100 fastq RNA-seq files (50 primary 
ccRCC and 50 normal adjacent renal samples, 
Supplementary Table 1) were downloaded from The 
Cancer Genome Atlas (TCGA) legacy archive (https://
portal.gdc.cancer.gov/legacy-archive/search/f). Human 
cDNA and ncRNA FASTA formatted transcript files 
(Ensembl v89 annotation) were acquired form the Ensembl 
ftp site (https://www.ensembl.org/info/data/ftp/index.
html), and merged to create a master file of all putative 
coding and non-coding transcripts. All quantification and 
differential expression analyses were performed using the 
kallisto-sleuth pipeline. Using the default settings, kallisto 
was used to create an index for quantification using the 
aforementioned FASTA master file. Subsequently, kallisto 
was used to quantify all putative transcripts using 50 
bootstrap samples. Differential expression analysis was 
performed with sleuth using the Wald test with a cutoff 
q-value of 0.005. RATs was performed using the read 
counts and bootstrap values calculated from kallisto. As 
ccRCC is a highly heterogeneous cancer, and there are 
4 major subtypes of ccRCC, a replicate reproducibility 
of 0.25 was used in the analysis. All other parameters 
remained on default settings.
For the edgeR analysis, alignment of the fastq files 
was performed first with HISAT2 using the hg38 human 
assembly [37–39]. Read counting was performed using the 
summarizeOverlaps package, with union mode [40]. Using 
the read counts, an edgeR analysis was performed using 
the default settings. The entire pipeline was performed 
within the systemPipeR package [41].
Weighted coexpression network analysis
All 217,082 TPM transcripts quantifications were 
initially filtered for an average absolute expression of 
> 1 TPM. Subsequently, 10,000 of the most variable 
transcripts, using the mean absolute deviation, were 
used for the proceeding WGCNA pipeline [42]. A soft 
thresholding power of 6 was used in a signed transcript 
coexpression network framework. All other parameters 
remained on the default recommended settings. ccRCC 
correlated coexpression networks were exported to 
VisANT with an adjacency threshold 0.08 for visualization 
purposes [43]. For the gene-level Metascape analysis 
(http://metascape.org) of each of the network modules, 
genes were considered only once in the analysis, regardless 
of the numbers of transcripts derived from the gene.
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Primer design and quantitiative PCR
Primers sequences were designed using Primer3 
plus (http://primer3plus.com/cgi-bin/dev/primer3plus.
cgi) using the default qPCR settings (Supplementary 
Table 1). When possible, primers were designed over 
exon junctions to avoid capturing unannotated alternative 
transcripts. All primers were synthesized by Integrated 
DNA Technologies. Twelve matched pair ccRCC RNA 
samples were acquired from Origene (Supplementary 
Table 1). Origene RNA samples were verified for 
quality and quantity using gel electrophoresis and the 
Thermoscientific Nanodrop2000 spectrophotometer. 
cDNA was synthesized using 1 ug of total RNA using 
the iScript reverse transcription supermix (Biorad, 
Irvine, CA) according to the manufacturer’s instructions. 
Quantitative PCR was performed using the Biorad iQ 
SYBR green supermix and a Biorad CFX Connect 
thermocylcer (Biorad, Irvine, CA) and analyzed using 
the CFX manager software. Using a single threshold 
Cq determination, the Livak method was employed for 
all gene expression analyses. All qPCR analyses were 
normalized to PPIA, as PPIA was shown to be a suitable 
reference gene when comparing normal adjacent tissue to 
ccRCC tumor tissue [44, 45].
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